A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Clinical trial NCT06672263 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06672263
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-01
- Primary completion
- 2026-09-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.